PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug
A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards (DHBs) over the next five years, says PHARMAC, New Zealand’s Pharmaceutical Management Agency.
Infliximab (Johnson & Johnson’s [NYSE: JNJ] Remicade) is a monoclonal antibody, one of the so-called “targeted drugs” used to treat auto-immune conditions like rheumatoid arthritis, inflammatory bowel diseases, and psoriasis. It is a high cost drug used in hospitals, with current spending in the region of NZ$15 million ($11.8 million) per year and growing rapidly.
Price reduction with the advent of biosimilars
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze